Literature DB >> 18456674

Remote ischaemic preconditioning: underlying mechanisms and clinical application.

Derek J Hausenloy1, Derek M Yellon.   

Abstract

Remote ischaemic preconditioning (RIPC) represents a strategy for harnessing the body's endogenous protective capabilities against the injury incurred by ischaemia and reperfusion. It describes the intriguing phenomenon in which transient non-lethal ischaemia and reperfusion of one organ or tissue confers resistance to a subsequent episode of lethal ischaemia reperfusion injury in a remote organ or tissue. In its original conception, it described intramyocardial protection, which could be relayed from the myocardium served by one coronary artery to another. It soon became apparent that myocardial infarct size could be dramatically reduced by applying brief ischaemia and reperfusion to an organ or tissue remote from the heart before the onset of myocardial infarction. The concept of remote organ protection has now been extended beyond that of solely protecting the heart to providing a general form of inter-organ protection against ischaemia-reperfusion injury. This article reviews the history and evolution of the phenomenon that is RIPC, the potential mechanistic pathways underlying its cardioprotective effect, and its emerging application in the clinical setting.

Entities:  

Mesh:

Year:  2008        PMID: 18456674     DOI: 10.1093/cvr/cvn114

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  166 in total

1.  Conditioned medium from hypoxic cells protects cardiomyocytes against ischemia.

Authors:  B Chanyshev; A Shainberg; A Isak; Y Chepurko; E Porat; E Hochhauser
Journal:  Mol Cell Biochem       Date:  2011-12-08       Impact factor: 3.396

2.  Endogenous cardioprotection by ischaemic postconditioning and remote conditioning.

Authors:  Weiwei Shi; Jakob Vinten-Johansen
Journal:  Cardiovasc Res       Date:  2012-02-09       Impact factor: 10.787

Review 3.  Remote ischemic preconditioning for kidney protection: GSK3β-centric insights into the mechanism of action.

Authors:  Zhangsuo Liu; Rujun Gong
Journal:  Am J Kidney Dis       Date:  2015-08-10       Impact factor: 8.860

Review 4.  Current protective strategies in liver surgery.

Authors:  Kurinchi S Gurusamy; Hector D Gonzalez; Brian R Davidson
Journal:  World J Gastroenterol       Date:  2010-12-28       Impact factor: 5.742

5.  Serum from patients undergoing remote ischemic preconditioning protects cultured human intestinal cells from hypoxia-induced damage: involvement of matrixmetalloproteinase-2 and -9.

Authors:  Karina Zitta; Patrick Meybohm; Berthold Bein; Christin Heinrich; Jochen Renner; Jochen Cremer; Markus Steinfath; Jens Scholz; Martin Albrecht
Journal:  Mol Med       Date:  2012-02-10       Impact factor: 6.354

6.  Preconditioning the human brain: practical considerations for proving cerebral protection.

Authors:  Sebastian Koch
Journal:  Transl Stroke Res       Date:  2010-09       Impact factor: 6.829

7.  Muscle microdialysis to confirm sublethal ischemia in the induction of remote ischemic preconditioning.

Authors:  Arzu Bilgin-Freiert; Joshua R Dusick; Nathan R Stein; Maria Etchepare; Paul Vespa; Nestor R Gonzalez
Journal:  Transl Stroke Res       Date:  2012-04-10       Impact factor: 6.829

8.  Effect of comprehensive remote ischemic conditioning in anterior ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Design and rationale of the CORIC-MI randomized trial.

Authors:  Li Song; Hongbing Yan; Peng Zhou; Hanjun Zhao; Chen Liu; Zhaoxue Sheng; Yu Tan; Chen Yi; Jiannan Li; Jinying Zhou
Journal:  Clin Cardiol       Date:  2018-08-16       Impact factor: 2.882

9.  Is nitrite the circulating endocrine effector of remote ischemic preconditioning?

Authors:  Paola Corti; Mark T Gladwin
Journal:  Circ Res       Date:  2014-05-09       Impact factor: 17.367

10.  Should the STAIR criteria be modified for preconditioning studies?

Authors:  Michael M Wang; Guohua Xi; Richard F Keep
Journal:  Transl Stroke Res       Date:  2013-02       Impact factor: 6.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.